COPENHAGEN, AUGUST 07, 2016 – Recent in vivo studies in mice documents the antibacterial properties of ATx201 and that they compare favorably to marketed products. The CSO of AntibioTx, Dr. Morten Sommer, said “ATx201 looks promising in numerous points such as treatment duration, de novo resistance and effectiveness against multi-drug resistant bacteria including MRSA. We strongly believe that ATx201 will be a valuable asset in treating microbiome related disorders”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.